Durcik, M.; Skok, Ž.; Ilaš, J.; Zidar, N.; Zega, A.; Szili, P.É.; Draskovits, G.; Révész, T.; Kikelj, D.; Nyerges, A.;
et al. Hybrid Inhibitors of DNA Gyrase A and B: Design, Synthesis and Evaluation. Pharmaceutics 2021, 13, 6.
https://doi.org/10.3390/pharmaceutics13010006
AMA Style
Durcik M, Skok Ž, Ilaš J, Zidar N, Zega A, Szili PÉ, Draskovits G, Révész T, Kikelj D, Nyerges A,
et al. Hybrid Inhibitors of DNA Gyrase A and B: Design, Synthesis and Evaluation. Pharmaceutics. 2021; 13(1):6.
https://doi.org/10.3390/pharmaceutics13010006
Chicago/Turabian Style
Durcik, Martina, Žiga Skok, Janez Ilaš, Nace Zidar, Anamarija Zega, Petra Éva Szili, Gábor Draskovits, Tamás Révész, Danijel Kikelj, Akos Nyerges,
and et al. 2021. "Hybrid Inhibitors of DNA Gyrase A and B: Design, Synthesis and Evaluation" Pharmaceutics 13, no. 1: 6.
https://doi.org/10.3390/pharmaceutics13010006
APA Style
Durcik, M., Skok, Ž., Ilaš, J., Zidar, N., Zega, A., Szili, P. É., Draskovits, G., Révész, T., Kikelj, D., Nyerges, A., Pál, C., Mašič, L. P., & Tomašič, T.
(2021). Hybrid Inhibitors of DNA Gyrase A and B: Design, Synthesis and Evaluation. Pharmaceutics, 13(1), 6.
https://doi.org/10.3390/pharmaceutics13010006